☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Fusion-Positive
Genentech' Gavreto (pralsetinib) Receives the US FDA's Approval Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
September 7, 2020
Chugai's Rozlytrek Receives MHLW's Approval for ROS1 Fusion-Positive Non-Small Cell Lung Cancer
February 21, 2020
Load more...
Back to Home
Modal title
×
Modal body text goes here.